Deraphan
Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry
Actionable Insights Powered by AI
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry